New drug combo could replace chemo for rare blood cancer
NCT ID NCT05099471
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether a combination of two drugs, venetoclax and rituximab, works better than standard chemotherapy for people with a rare blood cancer called Waldenström's macroglobulinemia who have not yet been treated. The study aims to see if this chemotherapy-free approach can achieve deeper responses and be given for a fixed time period, avoiding the need for continuous treatment. About 80 participants will be randomly assigned to receive either the new combo or standard chemo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Venetoclax and Rituximab
- What this could lead to
- If successful, this could offer a more effective, time-limited, chemotherapy-free treatment option for Waldenström's macroglobulinemia, potentially improving response rates and reducing side effects.
- What could go wrong
- This is a phase 2 trial with only 80 participants, so results are preliminary. The combination may not prove superior to standard therapy, and side effects like tumor lysis syndrome or infections are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TREATMENT NAIVE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Alexandra Hospital
RECRUITINGAthens, 115 28, Greece
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Christliches Klinikum Paderborn, Brüderkrankenhaus St. Josef Paderborn
RECRUITINGPaderborn, 33098, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Dr. Vehling-Kaiser MVZ GmbH
RECRUITINGLandshut, 84036, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Gemeinschaftsklinikum Mittelrhein gGmbH
RECRUITINGKoblenz, 56073, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Haematologie und Onkologie Muenchen-Pasing MVZ GmbH
RECRUITINGMünchen, 81241, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Kliniken Maria Hilf GmbH Moenchengladbach
RECRUITINGMönchengladbach, 41063, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Kliniken Ostalb, Standort Stauferklinikum Schwäbisch Gmünd
NOT_YET_RECRUITINGMutlangen, 73557, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Klinikum Chemnitz gGmbH
RECRUITINGChemnitz, 09116, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Klinikverbund Allgaeu gGmbH
RECRUITINGKempten, 87439, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Onkologische Schwerpunktpraxis Bielefeld
RECRUITINGBielefeld, 33604, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Universitaet Muenster
RECRUITINGMünster, 48149, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Universitaetsklinikum Schleswig-Holstein AöR
RECRUITINGKiel, 24105, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University Hospital Ulm
RECRUITINGUlm, 89081, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Universitätsmedizin Rostock
NOT_YET_RECRUITINGRostock, 18057, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Smartwatches track hidden heart risk in blood cancer patients
- Can a tailored exercise and diet plan beat cancer fatigue?
- Immunotherapy combo shows promise for Tough-to-Treat blood cancers
- New drug duo shows promise for rare blood cancer
- New hope for rare blood cancer: targeted drug shows promise in early trial
- Gut bacteria drug shows promise against blood disorder